Abstract: The present invention provides macrophages genetically modified to express IL-31 or both IL-31 and a chimeric antigen receptor (CAR) for treatment of cancer. It further provides methods for treatment of cancer comprising administration of IL-31 along with genetically unmodified macrophages or genetically modified to express a CAR.

Abstract: Provided are blocking agents to IL-1?, IL-1?, or IL-1R activity for use in combination with radiotherapy for treating cancer patients in which radiotherapy treatment induces IL-1?, IL-1? or both in their circulation.

Abstract: Methods of selecting a therapeutic agent to treat a cancer in a subject comprising receiving a plurality of protein data element values representing levels of the proteins in a biological sample from the subject, classifying each protein as a member of a process class, for each process class calculating a process score that represents the prominence of the process class to cancer treatment resistance and selecting at least one therapeutic agent that targets a selected process based on the process score. Systems for selecting a therapeutic agent are also provided.

Abstract: Provided are blocking agents to IL-1?, IL-1?, or IL-1R activity for use in combination with radiotherapy for treating cancer patients in which radiotherapy treatment induces IL-1?, IL-1? or both in their circulation.

Abstract: The present invention provides macrophages genetically modified to express IL-31 or both IL-31 and a chimeric antigen receptor (CAR) for treatment of cancer. It further provides methods for treatment of cancer comprising administration of IL-31 along with genetically unmodified macrophages or genetically modified to express a CAR.

Abstract: Provided are blocking agents to IL-1?, IL-1?, or IL-1R activity for use in combination with radiotherapy for treating cancer patients in which radiotherapy treatment induces IL-1?, IL-1? or both in their circulation.